BIIB vs CATY · P/E 21, rev $9.89B vs P/E 12, rev $30.4M
Biogen Inc (BIIB) versus Cathay General Bancorp (CATY) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Cathay General Bancorp (CATY) is a banks - regional company listed on US.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported CATY revenue for 2026-06-30 was $30.4M. Net income was $179.1M. CATY currently screens at market cap $3.90B and trailing P/E 12.0.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. CATY currently screens at market cap $3.90B and trailing P/E 12.0.
Not investment advice. Open the BIIB and CATY stock pages for the full models.
Not investment advice.